Amanta Healthcare Limited has launched its IPO worth Rs126 crore, that will open for registration on September 1st 2025. With a solid presence in the field of sterile liquid medicine as well as advanced packaging and exports to 21 countries, Amanta Healthcare IPO has caught the attention of investors who are focused on pharma. Here’s everything you should be aware of, including GMP developments to subscriber status, and even expert opinions.
Amanta Healthcare IPO Highlights
- The size of the IPO: Rs126 crore (Fresh issue is of one crore shares with a face Value of Rs10)
- Price Band Between Rs120 and Rs126 for each share
- Lot Size: 119 shares | Minimum Investment: Rs14,994
- Subscription Window: September 1 to 3, 2025
- Allotment Date: September 4, 2025
- Listing Date: September 8 or 9, 2025 (NSE & BSE)
- GMP (Grey Market Premium): Rs22-Rs25 above cap price, reflecting strong demand
Company Overview: Amanta Healthcare Limited
Amanta Healthcare is a leading pharmaceutical producer that is specialized in injections that are sterile IV fluids, Ophthalmic solutions and respiratory products.
- Utilizes cutting-edge technology such as Aseptic Blow-Fill Seal (ABFS) and Injection Stretch Blow Moulding (ISBM)
- Manufacturing facility located in Hariyala, Gujarat with seven production lines
- Exporting products to 21 markets around the world and backed by an local network of more than 320 stockists
This combination of cutting-edge technology and global reach position Amanta as a major competitor in India’s growing market for sterile formulations.
Financial Performance & Growth Outlook
- Rentability It was profitable for FY25, with Rs10.50 crore in profit (EBITDA margin of 22.11 percent)
- Revenues: Minor contraction, but a slight improvement in the RoE as well as RoCE by enhancing operational efficiency
- The Debt Situation: The ratio of equity to debt improved, by 3.43 (FY23) to 2.02 (FY25) however, it is still more than peers.
The overall picture displays improvement in its fundamentals, but the debt levels are still a source of concern.
IPO Objectives
The funds raised by an IPO can be used to:
- The project is worth Rs70 crore for SteriPort manufacturing line
- New production setup at Rs30 crore. SVP production set-up at the Hariyala facility
- The Balance is for general corporate purpose
Should You Subscribe to Amanta Healthcare IPO?
Strengths
- Strong position in the segment of sterile formulations
- A wide range of products and international certifications
- Growing focus on innovative packaging technology
Risks
- Reliance on the only one source
- The debt levels are still quite high.
- The challenges of regulatory compliance in many markets
Evaluation Notes: With 47x the FY25’s post-issue profits The IPO is deemed “fully priced.” However due to the sector’s longer-term growth prospects and Amanta’s reputation in the market analysts consider it an attractive option for pharma-focused investors.
How to Check Amanta Healthcare IPO Allotment Status
Investors can track the status of their IPO allotment status following September 4 2025 by using:
- IPO Registrar Website
- NSE/BSE IPO portals You must enter the PAN number, Demat and Application ID
FAQs on Amanta Healthcare IPO
Q1. Which is Amanta Health’s IPO price range?
This price range is set at the range of Rs120-R126 per share.
Q2. What is the GMP for Amanta Healthcare’s IPO currently?
At present at the moment, currently, Grey Market Premium (GMP) is currently trading between Rs22 to Rs25 over the cap price.
Q3. What is the Amanta Healthcare IPO day?
The IPO is scheduled to go public in Sept. 8-9 in 2025 on both NSE and BSE.
Q4. Should investors invest in this IPO?
The experts say that experts say that the IPO is relatively valued but is it is a promising thanks Amanta’s vast presence in the field of sterile medicine and its global presence.
Final Thoughts
Amanta Healthcare’s IPO is a blend of industry growth, better financials and international expansion but also carries some risks due to regulatory and debt hurdles. If you are an investor looking for opportunities in the pharmaceutical industry and opportunities, this IPO might be worth a look.
Disclaimer
This article is intended for informational reasons only and does not constitute financial advice. Investors should speak with an accredited financial advisor prior to making IPO investment decision.